

## PRIMER CURSO INTERAMERICANO DE ACTUALIZACIÓN EN NEUROLOGÍA

Advances in Diagnosis, Neurobiology, and Treatment of Neurological Disorders

University of Miami, March 20 and 21, 2017





#### Common Psychiatric Comorbidities in Epilepsy: What Every Neurologist *Must* Know and Do to Properly Treat Patients with Epilepsy

Andres M. Kanner, MD, FANA, FAES Professor of Clinical Neurology Head, Epilepsy Section, Director, Comprehensive Epilepsy Center University of Miami, Miller School of Medicine Miami, FL



## Learning Objective

Recognize the impact of psychiatric comorbidities on the management of the disorder in patients with epilepsy.

## Andres M. Kanner, MD, FANA, FAES

• Dr. Kanner has no disclosures to report.



# How big of a problem is it?

## **Lifetime Prevalence**

Psychiatric Disorder	Controls (%)	Epilepsy (%)
Major Depressive Disorder	10.7 (10.2–11.2)	17.4 (10.0–24.9)
Anxiety Disorder	11.2 (10.8–11.7)	22.8 (14.8–30.9)
Mood/Anxiety Disorders	19.6 (19.0–20.2)	34.2 (25.0–43.3)
Suicidal Ideation	13.3 (12.8–13.8)	25.0 (17.4–32.5)
Any Psychiatric Disorder	20.7 (19.5–20.7)	35.5 (25.9–44.0)

Tellez-Zenteno JF, et al. *Epilepsia*, 2007;48:2336-2344.































## **Peri-ictal Episodes...**

## **Ictal Psychiatric Symptoms**

- n = 100 pts. with "psychologic auras"
  - n = 21 with depression
  - n = 61 with fear
  - n = 18 with pleasurable or displeasurable emotions

Williams D. et al. Brain. 1956;79:29-67.

#### Panic disorder... or is it ictal panic?



## **Case Study**

- 34 year-old left handed man admitted following a first secondarily GTC
- Evaluated in ER; discharged on no meds. CT scan: read as unremarkable
- For the previous 7 years, the patient had complained of recurrent episodes of a "panic feeling" often associated with nausea lasting up to 1 minute
- After panic episodes, patient usually feels "emotionally exhausted" and had to take a nap

GTC = Generalized tonic seizure ER = Emergency room

## **Case Study**

- On days when he had a panic episode, concentration was poor.
- Panic episodes occurred in awake (75%) and sleep (25%) states.
- Patient's primary care physician interpreted the panic symptoms as anxiety disorder and placed him on alprazolam without relief of symptoms.
- Also treated with SSRIs.

#### **Clinical Differentiation Between Panic Disorder and Complex Partial Seizures**

	Panic Disorder Partial Seizure			
Consciousness	Usually preserved Impaired			
Agoraphobia	Common Very rare			
Duration of attack	>5 min	<120 seconds		
AEDs	Occasional helpful	Very often helpful		
Antidepressants	Helpful	Rarely worsen seizures		
Abnormal sleep-deprived interictal EEG	Usually absent	Often present		
Anticipatory anxiety	Common	Uncommon		
Automatisms	Uncommon	Common		

Handal NM, et al. Psychosomatics. 1995;36:498-501.

#### Number of Patients with Postictal Symptoms by Category

- N = 100
- Depression, n = 43
  - Postictal suicidal ideation, n = 13
- Anxiety, n = 45
- Psychosis, n = 7
- Neurovegetative, n = 62
- Cognitive, n = 82
- Cognitive without psychiatric, n = 14
- No Symptoms, n = 12

## **Postictal Symptoms of Depression**

Postictal symptom	Frequency (N = 100)	Duration (range, hrs)		
Poor Frustration	36	24 (0.5-108)		
Anhedonia	33	24 (0.1-148)		
Hopelessness	25	24 (1.0-108)		
Helplessness	31	24 (1.0-108)		
Crying Bouts	26	6 (0.1-108)		
Suicidal Ideation	13	24 (1.0-240)		
Irritability	30	24 (0.5-108)		
Guilt	23	24 (0.1-240)		
Self deprecation	27	24 (1.0-120)		
Any postictal symptom of depression, $n = 43$ patients				

Median number of symptoms: 5 (range: 2-9)

Kanner AM, et al. Neurology. 2004;62(5):708-713.

## **Postictal Symptoms of Anxiety**

Symptoms of Anxiety Total	N = 45	Median Duration (Range in Hours)
Constant worrying	33	24 (0.5 – 108)
Panicky feelings	10	6 (0.1 – 148)
Agoraphobic symptoms	29	24 (0.5 – 296)
Due to fear of seizure recurrence	20	-
Compulsions	10	15 (0.1 – 72)
Self consciousness	26	6 (0.05 – 108)

Kanner AM, et al. *Neurology.* 2004;62(5):708-713.



# Why should neurologists care?

### **Impact of Depression and Anxiety Episodes**

Increased mortality risk

Christiansen, et al. Lancet Neurol, 2007
Fazel, et al. Lancet 2013

Worse tolerance of antiepileptic drugs

Perucca, et al. Neurology 2011
Kanner, et al. Epilepsia 2012

Worse quality of life

Guilliam, et al. Neurology 2002
Kanner, et al. Epilepsia 2011

Increased risk of psychiatric iatrogenic adverse events

Mula, et al. Epilepsia 2003, 2007

#### **Impact of Depression and Anxiety Episodes**

- Worse seizure control with pharmacotherapy
  - Hitiris, et al. *Epilepsy Res*, 2007
  - Petrovsky, et al. Neurology 2010
  - Josephson, et al. JAMA Neurol, 2017
- Higher likelihood of persistent seizures after epilepsy surgery with antero-temporal lobectomies
  - Kanner, et al. *Neurology* 2009
  - Cleary, et al. *Epilepsia* 2012
  - De Araujo, et al. *Epilepsia* 2012

## **Old Assumption...**

In patients with epilepsy, depressive and anxiety disorders,
 Are a complication of the seizure disorder

#### **Bidirectional Relation Between Epilepsy and Psychiatric Disorders**

Patients with epilepsy have a 5- to 20-fold <u>higher risk</u> of developing depression



Patients with depression have a 2- to 5-fold <u>higher risk</u> of developing epilepsy

Hesdorffer DC, et al. *Ann Neurol.* 2006;59(1):35-41. Hesdorffer DC, et al. *Ann Neurol.* 2012;72(2):184-191.



## Are antidepressant drugs safe in patients with epilepsy?

## Impact of Mood Disorders and Antidepressant Drugs on the Occurrence of Spontaneous Seizures

- Assessment of seizure incidence between patients randomized to SSRIs, SNRIs, and placebo in regulatory studies
- Antidepressant treatments associated with <u>lower</u> seizure incidence relative to placebo for all SSRIs and SNRIs
- Standardized seizure ratio: 0.48, 95% CI 0.36-0.61
- The incidence of seizures among patients randomized to placebo was <u>19-fold higher</u> than that of the general population.

Alper K, et al. Biol Psychiatry. 2007;62(4):345-354.

### Higher Incidence of Seizures in Patients Exposed to Antidepressants than Placebo

- Clomipramine
- Bupropion immediate release (IR)

Alper K, et al. Biol Psychiatry. 2007;62(4):345-354.



## Glutamate

### **Glutamate in Depressive Disorders**

- <u>High</u> glutamate plasma and CSF concentrations
- Dysfunction of glutamate transporter proteins (identified in animal models of depression)
- Increased Cortical Glutamate identified in brain MRS
- Antidepressant effects of NMDA antagonists



## GABA

## **GABA Disturbances**

- <u>Decreased</u> CSF concentrations
- <u>Decreased</u> cortical concentrations in:
  - Post-mortem studies of patients with mood disorders
  - Brain MRS studies
    - Normalization of GABA concentrations has been demonstrated with antidepressant therapy and electroshock therapy
- *Decreased* GABA-A activity identified in studies with TMS:
  - Reduced silent period
  - Reduced intra-cortical inhibition



## Impact of **†HPA**

## **†HPA in Patients with Epilepsy**

- 16 patients with Temporal Lobe Epilepsy
- 16 patients with Major Depressive Disorder
- 16 healthy controls
- Lack of inhibitory control of the HPA system in patients with epilepsy and major depression.

Zobel A, et al. Eur Arch Psychiatry Clin Neurosci. 2004;254(5):303-311.

#### **Relation Between Duration of Depression and Hippocampal Volume Loss in Recurrent Depression**





#### Abnormalities of Frontal Lobe Structures

#### **Structural and Functional Abnormalities in the Frontal Lobe of Patients With Primary Depression**

- Structural changes in
  - Orbito-frontal and prefrontal cortex
  - Cingulate gyrus
  - White matter
- Smaller volume of orbito-frontal cortex in young adults and geriatric patients with Major Depressive Disorders
- The magnitude of prefrontal volume changes related to severity of the depression

#### Neuropathologic Findings in Frontal Lobe Structures in Primary Depression

#### • Decrease in

- Cortical thickness
- Neuronal sizes
- Neuronal densities in layers II, III, and IV of the rostral orbito-frontal region in the brains of depressed patients1
- In the caudal orbito-frontal cortex
  - Significant reductions in glial densities in cortical layers V and VI
  - Associated with decreases in neuronal sizes
- In the dorsolateral prefrontal cortex
  - A decrease in neuronal and glial density and size in all cortical layers

#### Neuroimaging Changes in Mesial Temporal Lobe Epilepsy are Magnified in the Presence of Depression

- To investigate differences in gray matter volume between patients with mesial temporal lobe epilepsy (MTLE) with and without depression using voxel-based morphometry.
- 96 neurologically healthy adult subjects and 48 people with MTLE participated in this study.
- 24 patients had MTLE with and 24 without major depression.
- The number of areas of gray matter volume loss was higher in patients with MTLE with depression than in those with MTLE without depression.

Salgado PC, et al. Epilepsy Behav. 2010;19(3):328-331.

## Areas with Significantly Greater Cortical Thinning in Depressed Patients with TLE

Laterality	Ρ
Bilateral	<.001
Left	<.001
Bilateral	<.001
Bilateral	<.001
Left	.016
Right	.023
Left	.03
	Laterality Bilateral Left Bilateral Bilateral Left Right Left

Salgado PP, et al. Epilepsia & Behavior 2010.



Identifying patients with epilepsy with depressive and / or anxiety disorders in the outpatient neurology clinic...

## Neurological Disorders Depression Inventory in Epilepsy (NDDI-E)

For the statements below, please circle the number that best describes you over the last two weeks including today

SYMPTOMS	Always or Often	Sometimes	Rarely	Never
Everything is a struggle	4	3	2	1
Frustrated	4	3	2	1
Nothing I do is right	4	3	2	1
Feel guilty	4	3	2	1
Difficulty finding pleasure	4	3	2	1
I'd be better off dead	4	3	2	1

A score of > 15 is suggestive of major depressive episode

Gilliam FG, et al. Lancet Neurol. 2006;5(5):399-405.

NDDI-E available at https://www.commondataelements.ninds.nih.gov/Doc/NOC/Neurological\_Disorders\_Depression\_Inventory\_in\_Epilepsy\_Link.pdf

## **Generalized Anxiety Disorder-7 (GAD-7)**

Please circle the number that best describes you over the last 2 weeks, including today

SYMPTOMS	Nearly every day	More than half the days	Several days	Not at all
Feeling nervous, anxious or on edge	3	2	1	0
Not being able to stop or control worrying	3	2	1	0
Worrying too much about different things	3	2	1	0
Trouble relaxing	3	2	1	0
Being so restless that it is hard to sit still	3	2	1	0
Being easily annoyed or irritable	3	2	1	0
Feeling afraid as if something awful might happen	3	2	1	0

A score of > 10 is suggestive of generalized anxiety disorder

Spitzer RL, et al. Arch Int Med. 2006;166:1092-1097.

GAD-7 available at http://www.integration.samhsa.gov/clinical-practice/GAD708.19.08Cartwright.pdf.

## Treatment...

- Pharmacotherapy
  - Cognitive behavior therapy
  - Both

#### Principle #1: Make Sure that the Depressive and Anxiety Episodes are Not the Expression of an latrogenic Effect...

- Introduction of AED with negative psychotropic properties in vulnerable patients.
- Increase dose of AED with negative psychotropic properties.
- Withdrawal of AED with positive psychotropic properties in vulnerable patients.
- Pharmacokinetic interaction between enzyme-inducing AED and concomitant psychotropic drug.

## **AEDs with Psychotropic Properties**

#### Positive

- Barbiturates
- Benzodiazepines
- Levetiracetam
- Topiramate
- Zonisamide
- Vigabatrine
- Tiagabine
- Perampanel

#### Negative

- Carbamazepine
- Valproic acid
- Oxcarbazepine
- Lamotrigine
- Gabapentin
- Pregabalin
- Benzodiazepines

### Principle #2: Aims of Pharmacotherapy...

- 1. Remission of all symptoms of depression and anxiety.
  - Can use screening instrument of symptoms of depression and anxiety
- 2. Adjust dose of antidepressant drug in the presence of enzyme-inducing antiepileptic drugs

## Pharmacotherapy of Depression and Anxiety Disorders in Epilepsy



## SSRIs and SNRIs with Antidepressant and Anxiolytic Properties

Antidepressant	Depression	Panic disorder	Generalised anxiety	Starting dose	Maximal dose
Paroxetine	+	+	+	10	60
Sertraline	+	+	+	25	200
Fluoxetine	+	+	+	10	80
Citalopram	+	+	+	10	60
Escitalopram	+	+	+	5	30
Venlafaxine	+	+	+	37.5	300
Duloxetine	+		+	40	120

#### **Psychiatric Comorbidities that Neurologists Should be Able to Provide Pharmacologic Treatment**

- Major depressive episode
  That is not part of a bipolar disorder
  Dysthymic disorder
- Generalized anxiety disorder
- Panic disorder

#### **Psychiatric Comorbidities that Neurologists Should Not Provide Pharmacologic Treatment**

- Patients with epilepsy with:
  - Bipolar disorder
  - Suicidal risk
  - Major depressive episodes that have failed to remit after two effective trials
  - Psychotic episodes



Can screening for depression and anxiety disorder facilitate their remission?

## Screening for Depression and Anxiety in the Outpatient Epilepsy Clinic

- N = 636 consecutive adults (age >18 old) with epilepsy.
- Normal intelligence.
- All patients completed at each visit:
- NDDI-E (to identify major depressive episodes)
- GAD-7 (to identify generalized anxiety disorder)
- Suicidality of the module of the MINI

### Screening for Depression and Anxiety in the Outpatient Epilepsy Clinic

- Six epileptologists reviewed the scores of these screening instruments
- Intervention included:
  - Referral to mental health professional
  - Start or adjust psychotropic drug
  - No change in treatment

### Screening for Depression and Anxiety in the Outpatient Epilepsy Clinic

- Changes in NDDI-E, GAD-7 and suicidality module of 115 patients between 2 consecutive visits investigated
- Percentage of patients whose scores of the NDDI-E, GAD and /or suicidality normalized between visits 1 and 2
- Number of patients with de-novo psychopathology at visit 2

#### Screening for Depression and Generalized Anxiety Disorder at the Rush Epilepsy Center

- N = 636 consecutive English-speaking adults
  - Age: ≥ 18 year-old
  - Gender: 54.5% women
- NDDI-E >15: 17.1%
- GAD-7 >10: 20.8%
- Only NDDI-E >15: 5.9%
- Only GAD-7>10: 9.6%
- Both: 11.2%

#### Changes in Psychiatric Comorbidites Between 2 Consecutive Visits

• N = 115

- Duration between the 2 visits: 123 ± 77 days
- Symptomatic on visit 1 with NDDI-E and /or GAD-7: <u>n = 40</u> (34.7%)
- Symptomatic on visit 2: <u>n = 15 (13%)</u>
- Previous history of depression, n = 25
- Previous treatment for depression, n = 21
- Previous history of anxiety, n = 24
- Previous treatment for anxiety, n = 20

#### Changes in NDDI-E, GAD-7 and NDDI-E + GAD-7 Scores Between 2 Visits: N = 115



## Points to Take Home...

In patients with epilepsy...

Mood and anxiety disorders are relatively frequent psychiatric comorbidities.

 They yield serious and negative impacts on the management of the seizure disorder and life of these patients at several levels.

- Worse seizure control
- Worse tolerance of AEDs
- Increased suicidal risk
- Worse quality of life

 Depression and anxiety can be safely treated with SSRIs and /or SNRIs.



## Questions Answers







PRIMER CURSO INTERAMERICANO DE ACTUALIZACIÓN EN NEUROLOGÍA

#### 

Provided by

